PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 45 Publications

13 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • a Expression and phosphorylation status of AKT and ERK1/2 and amount of cleaved CPP32 at 72 h after drug treatment were assessed by western blot. Actin was used to confirm equal protein loading. A representative experiment of three was reported. The panel shows cropped blots.

    J Hematol Oncol, 2017, 10(1):19. PD184352 (CI-1040) purchased from Selleck.

    The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)		 MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TidmlEPTB;MD6wNlI4PiEQvF2= NXLtbFA6W0GQR1XS
CHP-212 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jJc2lEPTB;MD6wNlg5PSEQvF2= NHfGZ|ZUSU6JRWK=
EoL-1-cell M2LUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W4dWlEPTB;MD6wOFE2OiEQvF2= MXPTRW5ITVJ?
DU-4475 NFrsU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDQTYlKSzVyPUCuNFc2QTlizszN MVPTRW5ITVJ?
MMAC-SF NYP4[IVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITlPZNKSzVyPUCuNVA6PzRizszN MUPTRW5ITVJ?
AGS NWTU[pI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMUG3NVMh|ryP M{jvdXNCVkeHUh?=
M14 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMUW0Olgh|ryP M17IcnNCVkeHUh?=
CP50-MEL-B MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPVU29jUUN3ME2wMlE4OjV2IN88US=> M1PjOHNCVkeHUh?=
C32 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMUmwO|Ih|ryP MnGyV2FPT0WU
KMOE-2 Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{e0RWlEPTB;MD6xPVc6PSEQvF2= MUHTRW5ITVJ?
A101D M3fiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz6TWM2OD1yLkKxOEDPxE1? NHTPV4tUSU6JRWK=
KM12 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[5cYg1UUN3ME2wMlI1ODV5IN88US=> MV3TRW5ITVJ?
HSC-4 NVvVPHZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PkVmlEPTB;MD6yOFM6PSEQvF2= NIjibW9USU6JRWK=
NOMO-1 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMkW3OFIh|ryP NEWzenZUSU6JRWK=
MZ7-mel NVPURYhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMk[zOEDPxE1? M3;vUnNCVkeHUh?=
ACN M1jw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMk[3N|ch|ryP NFHteI9USU6JRWK=
MEL-HO NUL3T21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PpXWlEPTB;MD6yO|Y2OiEQvF2= NVuxS5Z6W0GQR1XS
BHT-101 NWLORVNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfie49KSzVyPUCuNlg3ODZizszN M1SwTHNCVkeHUh?=
SK-MEL-28 NGH5W|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvtN2RpUUN3ME2wMlMxPDB7IN88US=> NH3lVpNUSU6JRWK=
KG-1 NWfVOpRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\CTWM2OD1yLkOwOlY5KM7:TR?= NHH1PIdUSU6JRWK=
COLO-679 M1H1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j3NmlEPTB;MD6zNlczKM7:TR?= NX\qSphxW0GQR1XS
SK-MEL-24 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwM{K4NVMh|ryP NH7aZndUSU6JRWK=
G-361 NHfOU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr3TWM2OD1yLkO2O|k2KM7:TR?= MXzTRW5ITVJ?
KY821 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPnTWM2OD1yLkO3PVEh|ryP M2XmfHNCVkeHUh?=
KASUMI-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTlSWJKSzVyPUCuN|k6KM7:TR?= NFvlcoFUSU6JRWK=
HL-60 M{W4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEiyPI5KSzVyPUCuOFEyODdizszN NGnHZVFUSU6JRWK=
K5 NVzZXXF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYToO4J2UUN3ME2wMlQ{OTF5IN88US=> M33kVnNCVkeHUh?=
KU812 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XWRWlEPTB;MD60OVI6QSEQvF2= NUjCbYhiW0GQR1XS
SH-4 NVOxdHZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\QWnVKSzVyPUCuOFYzPTZizszN MVXTRW5ITVJ?
HTC-C3 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[0TWM2OD1yLkS2OVMyKM7:TR?= NV;lZW5zW0GQR1XS
CP66-MEL NYXiVnBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnoW2NKSzVyPUCuOFg5ODlizszN MYDTRW5ITVJ?
WM-115 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXhdndDUUN3ME2wMlQ6OjV5IN88US=> MXrTRW5ITVJ?
A2780 M2KxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwNEm4NlMh|ryP MV;TRW5ITVJ?
P12-ICHIKAWA MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnoTWM2OD1yLk[xNlIyKM7:TR?= MXnTRW5ITVJ?
HMV-II NUPwNY1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M373OGlEPTB;MD62OFQ3PSEQvF2= MmTlV2FPT0WU
HT-144 M4rqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf0U2dSUUN3ME2wMlY1PjV5IN88US=> MX;TRW5ITVJ?
LB2518-MEL MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\GTWM2OD1yLkexOlMzKM7:TR?= NEX0[2dUSU6JRWK=
NCI-SNU-1 Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTGcVFrUUN3ME2wMlc2PDN|IN88US=> Mo[zV2FPT0WU
C2BBe1 M4LMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7GV4dKSzVyPUCuPFExOjNizszN NGDVXlRUSU6JRWK=
PSN1 NVO3dnI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjrcphKSzVyPUCuPVYyQTZizszN NVPCN2llW0GQR1XS
UACC-257 NVq5bHRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f4dGlEPTB;MD65OlQ4OyEQvF2= MVPTRW5ITVJ?
RVH-421 NWXLc49VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTtdVJjUUN3ME2wMlk4OThizszN MWrTRW5ITVJ?
GP5d NF\BRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwOUizNFgh|ryP NWDGXVR{W0GQR1XS
TYK-nu NFG2VGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETOOlBKSzVyPUGuNFMyPzJizszN NF61WpNUSU6JRWK=
SK-N-AS M{jGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwMEe5OFch|ryP M2W3XHNCVkeHUh?=
SW620 NEXFPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLXSVRKSzVyPUGuNVM2OzRizszN MVnTRW5ITVJ?
HuP-T4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3GTWM2OD1zLkG4N|U6KM7:TR?= NFmweWJUSU6JRWK=
A549 NELwcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjDSlBKSzVyPUGuNVk2PzZizszN M4HsSnNCVkeHUh?=
Mewo NFzNTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVntdY1ZUUN3ME2xMlIxOjd4IN88US=> MnTGV2FPT0WU
ONS-76 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrGTWM2OD1zLkKyNFQ6KM7:TR?= M2jme3NCVkeHUh?=
SK-MEL-1 MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO3OWFnUUN3ME2xMlI{PDF7IN88US=> NXLZTVZ6W0GQR1XS
RCM-1 NWjTUplCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnOTYQxUUN3ME2xMlI1ODR5IN88US=> MXPTRW5ITVJ?
H-EMC-SS MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTFwMkm2NFgh|ryP NILTXllUSU6JRWK=
NCI-H2291 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW3TWM2OD1zLkOyOVM3KM7:TR?= Mm\zV2FPT0WU
SW1463 NYXWdHJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP6WppKSzVyPUGuN|M4OjFizszN MUnTRW5ITVJ?
LS-411N NUL4NVVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3aTWM2OD1zLkSwOVE4KM7:TR?= NYLSXW9xW0GQR1XS
BV-173 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm4ZVd7UUN3ME2xMlQ1ODF3IN88US=> NWnBNFc5W0GQR1XS
LS-513 M3q1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17USmlEPTB;MT60OVE6OiEQvF2= NH;hU3dUSU6JRWK=
LoVo NVXKSWJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHRTWM2OD1zLkS2N|k6KM7:TR?= M37RUHNCVkeHUh?=
HO-1-N-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnO0TWM2OD1zLkWxOlM1KM7:TR?= MoHIV2FPT0WU
ML-2 NWizW|NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFwNUK4Olgh|ryP MkC1V2FPT0WU
NCI-H1437 NYrMWYZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle2TWM2OD1zLkW1Nlc2KM7:TR?= Mor5V2FPT0WU
SW1116 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf0bWtiUUN3ME2xMlU3Ozl6IN88US=> Ml;uV2FPT0WU
A4-Fuk M17hbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jz[mlEPTB;MT61O|A1PSEQvF2= M1Xv[HNCVkeHUh?=
HD-MY-Z MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwNUezO|Yh|ryP NHrXPYdUSU6JRWK=
SK-MEL-2 M2T2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXsTWM2OD1zLkW3OFU6KM7:TR?= NYXvd3JLW0GQR1XS
RT-112 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nj[GlEPTB;MT61PFk2OiEQvF2= NH3QNJlUSU6JRWK=
COLO-829 NInpVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTFwNkKyN|Ih|ryP MlvTV2FPT0WU
OVCAR-5 NVr0ZWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwN{e2PFch|ryP MnvyV2FPT0WU
NB69 NYruT3dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHuUmh5UUN3ME2xMlc5PDZ7IN88US=> NGTFZ4lUSU6JRWK=
NCI-H292 M3TkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV60[3ZPUUN3ME2xMlg3Pjl7IN88US=> NUDQU2ZlW0GQR1XS
LOXIMVI MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwOEm0Nlch|ryP NXH5SYNrW0GQR1XS
BPH-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfjcnR[UUN3ME2xMlg6PTlzIN88US=> NF\2O21USU6JRWK=
A375 M1Hzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\UTWM2OD1zLki5O|E1KM7:TR?= NEL4OYhUSU6JRWK=
LCLC-97TM1 M{Llfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXZfGFJUUN3ME2xMlkzOjV4IN88US=> NH;FR3FUSU6JRWK=
RXF393 MkP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlizTWM2OD1zLkm3PFg4KM7:TR?= M13nfHNCVkeHUh?=
HCC70 NXrFTodDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDsUVF5UUN3ME2yMlAzPDJ4IN88US=> NFOzboNUSU6JRWK=
EM-2 NVfPTWlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[5VppKSzVyPUKuNFcyQThizszN MVLTRW5ITVJ?
MZ2-MEL M4n1Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr4XVBKSzVyPUKuNVEyOjdizszN NYLrS4I{W0GQR1XS
HN MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVOxUGc3UUN3ME2yMlE3Ojd6IN88US=> M4D6e3NCVkeHUh?=
A2058 NEfWOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[yT29LUUN3ME2yMlE6Ojd7IN88US=> NVe5SotWW0GQR1XS
NB7 NULPOpFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSzTWM2OD1{LkO0NFg3KM7:TR?= M3ftOHNCVkeHUh?=
DOK NUL3WZB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojVTWM2OD1{LkO1O|c{KM7:TR?= NH3afI1USU6JRWK=
CAL-27 M4HoS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjpRYdjUUN3ME2yMlM6OjN4IN88US=> MYDTRW5ITVJ?
BB65-RCC NEf4bFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG5TWM2OD1{LkSwOlc1KM7:TR?= MV7TRW5ITVJ?
RD NHXV[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK1PHZKSzVyPUKuOFQ4OjNizszN NXXBfYhJW0GQR1XS
KNS-62 M3\QW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:3XYVbUUN3ME2yMlUyOTZ2IN88US=> NXTHPGdOW0GQR1XS
EW-13 NEK4O3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTJwNU[zN|kh|ryP MVrTRW5ITVJ?
DB NVmxNYVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Hv[2lEPTB;Mj61PFc5QCEQvF2= MonqV2FPT0WU
HCC2218 NHP6NJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O5cGlEPTB;Mj62OFc4QCEQvF2= M2PGZ3NCVkeHUh?=
L-363 MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHldldKSzVyPUKuO|Q{PyEQvF2= MnWyV2FPT0WU
CHL-1 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPqS|ZKSzVyPUKuPFA4QDVizszN MX7TRW5ITVJ?
BFTC-905 M{m1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\ZcFNKSzVyPUKuPFI2OyEQvF2= NGm1PGFUSU6JRWK=
HCE-T MnHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES0N4JKSzVyPUKuPFMzPjRizszN MXrTRW5ITVJ?
COLO-792 NWflT|R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHob4tKSzVyPUKuPFQxOjdizszN MkLuV2FPT0WU
LB2241-RCC M2fwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJwOEW4PVMh|ryP MnrRV2FPT0WU
CAL-39 M2Wz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjGTWM2OD1{Lki5PVk6KM7:TR?= MnjiV2FPT0WU
T-24 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\h[pRCUUN3ME2yMlkyOTF{IN88US=> MkXmV2FPT0WU
NCI-H727 M{\TW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nlS2lEPTB;Mj65NVc6PiEQvF2= NWTQRYdFW0GQR1XS
Ca9-22 NEDoendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSySmVvUUN3ME2yMlk4OjV3IN88US=> M3KyXHNCVkeHUh?=
MIA-PaCa-2 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTNwMEC3PFEh|ryP MWTTRW5ITVJ?
HT-1080 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTTTWM2OD1|LkCxPVk4KM7:TR?= MnPjV2FPT0WU
D-423MG NGnYdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXCe5E2UUN3ME2zMlA4PzV|IN88US=> M2HTfnNCVkeHUh?=
LAMA-84 M{LBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f3XGlEPTB;Mz6xN|U5KM7:TR?= NHHwblFUSU6JRWK=
SW780 MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\aTWM2OD1|LkG0NlI6KM7:TR?= NIHNdmlUSU6JRWK=
KU-19-19 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zaOWlEPTB;Mz6xO|A{PCEQvF2= MVPTRW5ITVJ?
COLO-741 NUHkTYNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\oPVBKSzVyPUOuNVg3PzNizszN M2L4RXNCVkeHUh?=
HSC-3 NHX2OoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfVeXRWUUN3ME2zMlI{OTVzIN88US=> NILLbVhUSU6JRWK=
SN12C MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nGOmlEPTB;Mz6yOFcxOSEQvF2= Mnf2V2FPT0WU
786-0 NVr2SXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnEd41YUUN3ME2zMlI4OjR|IN88US=> M1vRbnNCVkeHUh?=
GAK NGDEXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwM{K1OlEh|ryP MkfqV2FPT0WU
PANC-03-27 NGraV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwM{WwOFUh|ryP M{X5eXNCVkeHUh?=
CTB-1 NHO3eZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTNwNEewOFch|ryP NH:0bmdUSU6JRWK=
A427 NI\RV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwNUm1OVYh|ryP NHjkfIlUSU6JRWK=
EGI-1 M1u2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTNwNkC1PFMh|ryP NVHUVGZ1W0GQR1XS
U-2-OS MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm2TWM2OD1|Lk[3NlU3KM7:TR?= MYXTRW5ITVJ?
NCI-SNU-5 NISyWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\OXJZNUUN3ME2zMlY4PzNizszN MoXLV2FPT0WU
SK-LU-1 M{Xiemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fyVGlEPTB;Mz62PFc6QCEQvF2= MXLTRW5ITVJ?
697 M4j4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTNwNkm2NFMh|ryP NF\1cGtUSU6JRWK=
HPAF-II M37GbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr4U3dwUUN3ME2zMlc2PDlizszN MYHTRW5ITVJ?
NCI-H2087 NIWyem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X2cGlEPTB;Mz64OFY4OiEQvF2= NInMTY9USU6JRWK=
SK-MEL-3 NEP3OolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfjc5FKSzVyPUOuPFUyPTRizszN MWHTRW5ITVJ?
CGTH-W-1 M4DabWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PiZ2lEPTB;Mz64OVczPSEQvF2= NGmyU3BUSU6JRWK=
8505C MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uwOGlEPTB;Mz65NFA4QCEQvF2= Mn76V2FPT0WU
GAMG MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrZTWM2OD12LkCyN|c4KM7:TR?= NF7jNWtUSU6JRWK=
SW626 NVr2d|ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP0cndKSzVyPUSuNFQ1QCEQvF2= NH3rfoZUSU6JRWK=
CAL-62 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTRwMEe0N{DPxE1? M2P4RXNCVkeHUh?=
MHH-PREB-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjMVVlNUUN3ME20MlEzOTFzIN88US=> M3\se3NCVkeHUh?=
RPMI-7951 NIHzOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPjW4dqUUN3ME20MlI2PTh7IN88US=> NV33[lJoW0GQR1XS
HOP-92 M4DFS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTRwMkW2O{DPxE1? NWHEfYQ1W0GQR1XS
MDA-MB-231 NV[1N|k{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTRwMkmyNlMh|ryP MoHWV2FPT0WU
LAN-6 NXKwU4xHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTRwM{G2N|ch|ryP MXvTRW5ITVJ?
ALL-PO M37vU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonpTWM2OD12LkO2NVU3KM7:TR?= MYTTRW5ITVJ?
HH M2fhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfTO|dwUUN3ME20MlQyPTl5IN88US=> NV;pfItVW0GQR1XS
IGROV-1 NUT3TItYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVW1VG1nUUN3ME20MlQ2OTdzIN88US=> MnHTV2FPT0WU
NCI-H358 M1npfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXe3UIdqUUN3ME20MlQ2Ozh3IN88US=> Mn;2V2FPT0WU
NB5 M1XUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRwNkCzOlkh|ryP MX3TRW5ITVJ?
NCI-H747 NYXHc3NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHMTWM2OD12Lk[4PFA4KM7:TR?= MkjmV2FPT0WU
NH-12 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTRwN{G2NlUh|ryP M1fmR3NCVkeHUh?=
LB1047-RCC NETGfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3RR2cxUUN3ME20Mlc{QDF3IN88US=> M{DvW3NCVkeHUh?=
EFO-27 M1[1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLQTWM2OD12Lke4OlY4KM7:TR?= M2rTUHNCVkeHUh?=
EPLC-272H MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLa[YZKSzVyPUSuPVk3PjlizszN NIfYOVdUSU6JRWK=
CAL-54 NHe4OGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\3TGlEPTB;NT6wNlY6PSEQvF2= MXfTRW5ITVJ?
H4 NEnXcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLwTWM2OD13LkC0NlU2KM7:TR?= MX7TRW5ITVJ?
MOLT-13 Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H6WGlEPTB;NT6wOlc4PiEQvF2= M2LjbXNCVkeHUh?=
CAL-33 NUfuW49lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H3UGlEPTB;NT6xNlMyPyEQvF2= MoPEV2FPT0WU
23132-87 NVzXS2ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:wdVJKSzVyPUWuNVY5PzJizszN Ml7wV2FPT0WU
UM-UC-3 M2DXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrDd41rUUN3ME21MlE5ODR5IN88US=> NXnVWlRwW0GQR1XS
HuH-7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPkVXBwUUN3ME21MlI4OTR5IN88US=> MVHTRW5ITVJ?
BCPAP MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTVwM{K5Olkh|ryP NVTKU5hUW0GQR1XS
AsPC-1 M4rlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonITWM2OD13LkO2O|Y{KM7:TR?= M{PLSHNCVkeHUh?=
NCI-H1155 NEfFWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\ReVJKSzVyPUWuOFAxPTFizszN NWe5XZVDW0GQR1XS
GT3TKB NEWw[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jGSWlEPTB;NT60OlU6QCEQvF2= MWPTRW5ITVJ?
HCC2998 M3iySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTVwNEmxNFkh|ryP MnfiV2FPT0WU
NUGC-3 M3n3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTVwNEmzNFIh|ryP NVS2eZNvW0GQR1XS
Hs-578-T NIjDRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFqwWGlKSzVyPUWuOVM4QTRizszN MWPTRW5ITVJ?
FADU M4fm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfCWGhKSzVyPUWuOVU4OjZizszN MWnTRW5ITVJ?
NBsusSR NG\wNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjINZpKSzVyPUWuOVcyPTVizszN NVjrW|FrW0GQR1XS
ME-180 NFPibFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XVbWlEPTB;NT61PFA6OiEQvF2= M3XIdXNCVkeHUh?=
SW1710 MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTVwNkG2OVQh|ryP NGnBXo9USU6JRWK=
HuP-T3 M3yycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW5TWM2OD13Lk[yNFI6KM7:TR?= NH\xd4VUSU6JRWK=
HOS M{DP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDSTWM2OD13Lk[yPVI{KM7:TR?= NYXLOI9MW0GQR1XS
PA-1 M3f0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP4NI5KSzVyPUWuOlQzPjVizszN M3P1XnNCVkeHUh?=
LU-99A Mln5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDFdoxYUUN3ME21MlY3PDVzIN88US=> MkfWV2FPT0WU
RS4-11 Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjkd445UUN3ME21MlY3Pzd3IN88US=> M2fyNnNCVkeHUh?=
TE-8 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S1TWlEPTB;NT62PFU{PyEQvF2= MoTsV2FPT0WU
RERF-LC-MS NYfCdYJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTVwNki4NFMh|ryP NEjKN2VUSU6JRWK=
MEL-JUSO MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTVwN{O3PEDPxE1? NGf2S4xUSU6JRWK=
SK-MES-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[wU2xKSzVyPUWuPFM2OjhizszN NUfaOGFRW0GQR1XS
D-263MG NHrNb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn2wTWM2OD13Lki4N|UyKM7:TR?= M2LqcXNCVkeHUh?=
NB10 M{W1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[2TWM2OD13Lki5OFYh|ryP NX22OWFWW0GQR1XS
SK-HEP-1 M4XROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rR[2lEPTB;NT65N|Q4OSEQvF2= NGnQSlRUSU6JRWK=
HT-29 M2HWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTGTWM2OD13Lkm4NVE5KM7:TR?= NGjnSpdUSU6JRWK=
KYSE-140 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZwMEKxPFIh|ryP NIf4eWVUSU6JRWK=
NCI-H1666 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3no[WlEPTB;Nj6wPFQ3OSEQvF2= NU\LRoVXW0GQR1XS
NCI-H1304 M17nSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn73TWM2OD14LkG5PVQh|ryP MVHTRW5ITVJ?
RPMI-8866 NXi3TodPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXi1UY9wUUN3ME22MlIyOzF|IN88US=> M4m3OHNCVkeHUh?=
MV-4-11 NUXZOZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVGwXIo6UUN3ME22MlI{OTl7IN88US=> NWnYOW5VW0GQR1XS
A431 NHHlb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\ZeFRKSzVyPU[uNlQzQTZizszN MoTtV2FPT0WU
PANC-10-05 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTZwMkizOlMh|ryP NXn3VGp6W0GQR1XS
TK10 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZwM{K2NFQh|ryP M4XHWHNCVkeHUh?=
NCI-H1975 NWXGUodYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonqTWM2OD14LkS3NlE2KM7:TR?= MWjTRW5ITVJ?
A172 NE\MfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zLe2lEPTB;Nj60PVE4PiEQvF2= M2DhNnNCVkeHUh?=
D-566MG MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITTOlRKSzVyPU[uOVQ{ODNizszN MmD2V2FPT0WU
NCI-H2122 M4i2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DTSWlEPTB;Nj62NVUzQCEQvF2= NYGxOYZ6W0GQR1XS
COR-L105 NEjMenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;Ib212UUN3ME22MlY2Ojd3IN88US=> NUOzO2F7W0GQR1XS
AN3-CA NFfRUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml61TWM2OD14Lk[4OlQyKM7:TR?= MXLTRW5ITVJ?
Calu-6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[zTWM2OD14Lke5Olk5KM7:TR?= NGnkZZlUSU6JRWK=
HCT-116 NYTTdlBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDGNXNKSzVyPU[uPFEzPjRizszN MlnJV2FPT0WU
MHH-NB-11 NWDONW46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\pe2lEPTB;Nj64OVAxOiEQvF2= MUDTRW5ITVJ?
MFE-280 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHRc4tEUUN3ME22Mlg2QTh|IN88US=> Mn3CV2FPT0WU
SW1088 NWPJSFRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3UTWM2OD14LkmxPVE{KM7:TR?= Mn;6V2FPT0WU
SW48 MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfzTWM2OD14Lkm0OVEh|ryP NV\lUmJIW0GQR1XS
HuCCT1 NWLKWpJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TQVmlEPTB;Nz6wNVA{PyEQvF2= NGTne3RUSU6JRWK=
ACHN NHnCVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PJU2lEPTB;Nz6wNlk1OyEQvF2= NWPQVHNPW0GQR1XS
8305C Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\EemlEPTB;Nz6wPVk6PSEQvF2= M4HZOHNCVkeHUh?=
DoTc2-4510 NITKSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTdwMUKxOUDPxE1? NWq5S2NFW0GQR1XS
COR-L23 NVKwc|I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXZeVVnUUN3ME23MlI1PDJizszN NFfrboNUSU6JRWK=
SK-MEL-30 NYD5[2hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTdwMkWwPFMh|ryP NGDNTVVUSU6JRWK=
BE-13 NUTVPG1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHF[IJtUUN3ME23MlM{QDN2IN88US=> MYHTRW5ITVJ?
GR-ST MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuyfYJKSzVyPUeuOFAyPzRizszN MYLTRW5ITVJ?
LU-135 NH7Dbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPJTWM2OD15LkW1PVM6KM7:TR?= Ml21V2FPT0WU
U-266 M3vxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTdwNU[yPFYh|ryP NFraXXhUSU6JRWK=
NCI-H1355 NVfXS|B{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHOd|A3UUN3ME23MlU5PjN3IN88US=> MlTvV2FPT0WU
NB14 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OyTmlEPTB;Nz62OlY1OiEQvF2= M4KzdXNCVkeHUh?=
SCC-25 NGPrNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTdwN{C5JO69VQ>? NVXLWYdSW0GQR1XS
COLO-678 NXq5TIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3FbndTUUN3ME23MlcyODd4IN88US=> M3rQ[nNCVkeHUh?=
TGBC1TKB MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDmUlBEUUN3ME23Mlg6Ozl6IN88US=> NHXzdXRUSU6JRWK=
IST-MEL1 NHrpbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVn1S29JUUN3ME24MlAxPDB4IN88US=> MVLTRW5ITVJ?
ECC10 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRThwMEOzPVUh|ryP NFS4OJZUSU6JRWK=
EW-16 NY\sWJo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PkeGlEPTB;OD6wPFQ1PSEQvF2= M{TVdXNCVkeHUh?=
DOHH-2 MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRThwMkCwPVUh|ryP MnizV2FPT0WU
NCI-H1581 MkXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TWSGlEPTB;OD6yOlMzOyEQvF2= MnXqV2FPT0WU
TE-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fhfmlEPTB;OD60NlQzQSEQvF2= M1vndnNCVkeHUh?=
CAKI-1 M2XRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXnTWM2OD16LkW3NlIzKM7:TR?= NGT6flJUSU6JRWK=
A673 M1\kTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjYWYRKSzVyPUiuOlMzODJizszN MmfhV2FPT0WU
CAL-12T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRThwNkW3OVMh|ryP NELLfY1USU6JRWK=
DBTRG-05MG NIXv[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRThwN{S4OVkh|ryP M2PSeHNCVkeHUh?=
SK-N-FI M2D1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRThwOEGzO|kh|ryP MWTTRW5ITVJ?
K-562 M37UdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[4NFJKSzVyPUiuPFM6PTdizszN NGC1c4pUSU6JRWK=
SBC-1 NIfSWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXhb3VKSzVyPUiuPFY3PDVizszN M13x[3NCVkeHUh?=
ES4 NFvEfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLXTWM2OD16Lki2PFg1KM7:TR?= MWXTRW5ITVJ?
MS-1 NWK0XoRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRThwOEe1NVch|ryP M37SNHNCVkeHUh?=
RKO M4i2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;JTWM2OD16Lki5NFU4KM7:TR?= MorBV2FPT0WU
NCI-H1693 NWPGZm1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHxS4ZKSzVyPUiuPVIyPyEQvF2= M{HGTnNCVkeHUh?=
SW954 NFv1SYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnC[nhOUUN3ME24Mlk3QTd6IN88US=> NFHBellUSU6JRWK=
SK-UT-1 Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[4fGlEPTB;OD65O|Y5OyEQvF2= NXixVWw3W0GQR1XS
T98G M1LCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vvW2lEPTB;OD65PVg1PiEQvF2= MXXTRW5ITVJ?
NCI-H2126 MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTlwMEC4NlYh|ryP NXPaOYg3W0GQR1XS
TE-12 NFvjUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu2TWM2OD17LkCzN|Y4KM7:TR?= MYnTRW5ITVJ?
DK-MG NVPndYZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzkdolXUUN3ME25MlIyOTlzIN88US=> MmHFV2FPT0WU
MEG-01 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTlwMkS5N|Eh|ryP MWTTRW5ITVJ?
HCC1937 MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rUVWlEPTB;OT6yPVA6OSEQvF2= M3PRbnNCVkeHUh?=
MKN45 NXT1T|I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPDN5VQUUN3ME25MlQ2ODZ3IN88US=> Mm\UV2FPT0WU
NCI-H1792 M{P4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;OW5VqUUN3ME25MlQ2OjF7IN88US=> MnSxV2FPT0WU
SW1417 MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HrWGlEPTB;OT61Olg{PyEQvF2= NX\xPXVJW0GQR1XS
639-V MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELLfXJKSzVyPUmuOlQ{QDhizszN NH36e4dUSU6JRWK=
P30-OHK M{S4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3NTWM2OD17Lk[1N|E3KM7:TR?= MX3TRW5ITVJ?
YKG-1 NV7YWVNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF65dlhKSzVyPUmuO|UxOzNizszN MX\TRW5ITVJ?
KGN MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW0TWM2OD17LkizO|k2KM7:TR?= NHvZfnhUSU6JRWK=
MSTO-211H NYDpcWFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTlwOUW1Nlkh|ryP NYfZOWhoW0GQR1XS
NCI-H1573 NVG5V2E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nqVGlEPTB;MUCuNVU4PCEQvF2= MkT3V2FPT0WU
NCI-H720 NHjqe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTsbotKSzVyPUGwMlE6QDlizszN M1vT[HNCVkeHUh?=
KARPAS-45 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;k[JJKSzVyPUGwMlI4QTVizszN NWO5dnFmW0GQR1XS
MDA-MB-175-VII M{O4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HIOGlEPTB;MUCuOFgh|ryP NH72dpNUSU6JRWK=
SK-NEP-1 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PlTWlEPTB;MUCuOFk5OSEQvF2= MkPPV2FPT0WU
MKN28 NW\mPI9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFyLkWxPEDPxE1? NEnLZ5RUSU6JRWK=
KYSE-520 MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFyLkWyJO69VQ>? NGLRe2dUSU6JRWK=
KE-37 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf5cJo3UUN3ME2xNE42Ojd{IN88US=> M3v2dXNCVkeHUh?=
VA-ES-BJ MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fNTmlEPTB;MUCuOVY4KM7:TR?= MkTsV2FPT0WU
CCRF-CEM M{fIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDQZ|BmUUN3ME2xNE42Pjh2IN88US=> NWHtNFJLW0GQR1XS
GMS-10 MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFyLk[wPVQh|ryP NVHtbmpRW0GQR1XS
NCI-H1623 M1LvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXWNnBLUUN3ME2xNE43Ozd7IN88US=> Mli1V2FPT0WU
NEC8 NYOy[VdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLUOY9yUUN3ME2xNE44Pzd|IN88US=> M4TST3NCVkeHUh?=
MOLT-16 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17v[2lEPTB;MUCuPFEyOyEQvF2= NYLpdIVEW0GQR1XS
DJM-1 MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W4W2lEPTB;MUGuNFM4QSEQvF2= NX7qS|ZOW0GQR1XS
U251 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvVNIs{UUN3ME2xNU4xPDJizszN Mnn3V2FPT0WU
SBC-5 M{X0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHW[lVFUUN3ME2xNU4yPDZ5IN88US=> NWPJWIY6W0GQR1XS
SW756 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TNUmlEPTB;MUGuNlE2PCEQvF2= NVLjcXR6W0GQR1XS
KS-1 M3GyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXidlJQUUN3ME2xNU4zPjF7IN88US=> M1GzT3NCVkeHUh?=
SF295 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFzLkOxNFQh|ryP MXjTRW5ITVJ?
YH-13 M{PheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFzLkOyOlch|ryP MoPxV2FPT0WU
SW837 NUi5bYRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DwPGlEPTB;MUGuN|UxPiEQvF2= M4LHNnNCVkeHUh?=
KYSE-450 M4Wyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTMTWM2OD1zMT60NFU4KM7:TR?= NV:3[VBDW0GQR1XS
KYSE-180 MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rhVmlEPTB;MUGuOFgzKM7:TR?= NILwSYNUSU6JRWK=
S-117 NGDPdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHoRo93UUN3ME2xNU41QDl4IN88US=> NIjrXnFUSU6JRWK=
KOSC-2 NHnTXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFzLk[yNlIh|ryP MVjTRW5ITVJ?
KYSE-270 NFTxNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKwOI5nUUN3ME2xNU45PzR3IN88US=> MoXyV2FPT0WU
D-336MG Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFzLkmwO|Uh|ryP MUDTRW5ITVJ?
KALS-1 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPQTWM2OD1zMj6wNFE3KM7:TR?= M3HFdHNCVkeHUh?=
LB373-MEL-D Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPPTWM2OD1zMj6wOVM{KM7:TR?= MnTlV2FPT0WU
HLE NFfzUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33mZmlEPTB;MUKuNFU5PSEQvF2= NHTLV3FUSU6JRWK=
SJSA-1 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF{LkC3N|Uh|ryP MoPEV2FPT0WU
SW1990 MnGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fC[2lEPTB;MUKuNFkyOSEQvF2= NFrvc45USU6JRWK=
NOS-1 NE\tboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF{LkGzOVIh|ryP MlrOV2FPT0WU
GI-ME-N MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG0R|Z[UUN3ME2xNk4zOTZ|IN88US=> NF\2[JhUSU6JRWK=
NCI-H1703 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKxTWM2OD1zMj6yOlE3KM7:TR?= NYrGdVNLW0GQR1XS
ES7 NIjFXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF{LkK3NlQh|ryP M{ThPHNCVkeHUh?=
KYSE-510 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXyTWM2OD1zMj61NFc6KM7:TR?= MnvhV2FPT0WU
BHY MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf3OZhKSzVyPUGyMlU{ODdizszN MWjTRW5ITVJ?
TCCSUP M2T1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXrSVZKSzVyPUGyMlU4PTdizszN M1;w[XNCVkeHUh?=
HSC-2 NWLyUmN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrWTWM2OD1zMj61PVk3KM7:TR?= MXjTRW5ITVJ?
BEN MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LOZ2lEPTB;MUKuOlE1OyEQvF2= M{TZNHNCVkeHUh?=
769-P NVfEZ2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF{Lke5NlQh|ryP NYDNV5lSW0GQR1XS
HT M3;YN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[4V2lEPTB;MUKuPFM1PiEQvF2= M4fnUnNCVkeHUh?=
LXF-289 M{i1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnHSmlKSzVyPUGyMlk2OzFizszN M2izRnNCVkeHUh?=
OVCAR-3 NVr2XGxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\pXGlEPTB;MUKuPVU3PyEQvF2= M3y5ZnNCVkeHUh?=
ATN-1 M3rTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TjWmlEPTB;MUOuNFE5PCEQvF2= MnG0V2FPT0WU
8-MG-BA NGjXd3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi1T4lFUUN3ME2xN{4xPDV3IN88US=> NV;Mb2Z2W0GQR1XS
SW13 NFTVZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXkTWM2OD1zMz6xNVY2KM7:TR?= MWHTRW5ITVJ?
NCI-H1092 M{Tq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzxTJBKSzVyPUGzMlE3OiEQvF2= MX\TRW5ITVJ?
OAW-42 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j6SGlEPTB;MUOuNVk{PyEQvF2= NWTud3k3W0GQR1XS
NCI-H2452 M13jSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT5TWM2OD1zMz6yNVc2KM7:TR?= NInpWHhUSU6JRWK=
CAPAN-1 M4m1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7sN3plUUN3ME2xN{42PTF2IN88US=> MmDXV2FPT0WU
NCI-H2009 NIj6UHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrmSFI6UUN3ME2xN{42QTF7IN88US=> NH;rWmlUSU6JRWK=
SF268 Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X1bWlEPTB;MUOuOlMzPiEQvF2= M2PEXXNCVkeHUh?=
GCIY NGK2SpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\PNmlEPTB;MUOuOlkzPyEQvF2= NE[1RWpUSU6JRWK=
OS-RC-2 M2PFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7XbldKSzVyPUGzMlk2ODFizszN NVHlPJU6W0GQR1XS
GCT NHXj[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jScWlEPTB;MUOuPVY6PyEQvF2= Moj3V2FPT0WU
NB17 NVH2fIRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF2LkC4OUDPxE1? MV3TRW5ITVJ?
NCI-H2030 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS3TWM2OD1zND6xOFY2KM7:TR?= NY\Kd3VlW0GQR1XS
HC-1 NHOzVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXWyWmJGUUN3ME2xOE4zODh5IN88US=> M2OxOnNCVkeHUh?=
QIMR-WIL NH2xTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnj[5dKSzVyPUG0MlM1OTJizszN NIG2UGtUSU6JRWK=
Capan-2 NVTaUnZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITQXpNKSzVyPUG0MlM4OTRizszN NGnjWI9USU6JRWK=
BALL-1 NX;ENoFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLHTYVRUUN3ME2xOE41PjZ3IN88US=> MUnTRW5ITVJ?
LS-1034 NYKyNVFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF2Lk[xOVIh|ryP NGHQNmpUSU6JRWK=
U-118-MG MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK0TYhEUUN3ME2xOE43OzFizszN MmL3V2FPT0WU
NCI-H630 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnwPY1kUUN3ME2xOE43PTZ6IN88US=> MlrLV2FPT0WU
OVCAR-8 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\Y[FVRUUN3ME2xOE44OjBzIN88US=> MW\TRW5ITVJ?
NCI-H2347 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG1cYJKSzVyPUG0MlgzOyEQvF2= NYf4V41wW0GQR1XS
BT-549 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYflOmZuUUN3ME2xOE45Ojh2IN88US=> NWHPdYFWW0GQR1XS
LB831-BLC NV;4cFFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXITWM2OD1zND64PVM1KM7:TR?= NXLoW5JiW0GQR1XS
NCI-H661 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkC0TWM2OD1zND65OVkh|ryP MoDCV2FPT0WU
MKN7 M{fNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fGUmlEPTB;MUWuNFA6OyEQvF2= MW\TRW5ITVJ?
U-87-MG M1ftfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS4W2tKSzVyPUG1MlA5QTdizszN M1n6W3NCVkeHUh?=
OVCAR-4 NV3W[ZJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF3LkG0NlQh|ryP M3TqdXNCVkeHUh?=
OE33 MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTF3LkG3NVEh|ryP NUnYeFNbW0GQR1XS
EC-GI-10 M{fSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF3LkKzOVch|ryP MXvTRW5ITVJ?
AM-38 NFjQW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPobmhKSzVyPUG1MlI4OTdizszN Mn3BV2FPT0WU
NCI-H1563 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF3LkO0PUDPxE1? NWrvSXJlW0GQR1XS
SCC-4 NH7GdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rQXmlEPTB;MUWuOFExOyEQvF2= M3f5Z3NCVkeHUh?=
Detroit562 NF3jNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml20TWM2OD1zNT60OVQ4KM7:TR?= MnOwV2FPT0WU
PC-14 NVOyWpRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXnfWNUUUN3ME2xOU41QDZ4IN88US=> MnXrV2FPT0WU
ES3 NH6ybGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O4UWlEPTB;MUWuOVM3KM7:TR?= M2HVZnNCVkeHUh?=
OCI-AML2 NHjXUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF3Lke2NVQh|ryP MYDTRW5ITVJ?
LU-134-A MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr4XnFzUUN3ME2xOU46ODF6IN88US=> NEXWXWFUSU6JRWK=
SAS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2CxSGlEPTB;MUWuPVM4OyEQvF2= NYPWW5JkW0GQR1XS
TGBC11TKB MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnSdo9KSzVyPUG1Mlk1OTRizszN MW\TRW5ITVJ?
HOP-62 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjUN2dKSzVyPUG1Mlk2QTdizszN NEnndXlUSU6JRWK=
G-401 NIPKfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTF3Lkm2OFkh|ryP MmPoV2FPT0WU
NCI-H28 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\YTWM2OD1zNj6wPFU3KM7:TR?= M3zWRnNCVkeHUh?=
A204 NV7PT3NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzLWYpKSzVyPUG2MlIxODZizszN M3rvSHNCVkeHUh?=
NCI-H1299 M1LhW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ThbmlEPTB;MU[uNlI6OSEQvF2= NUHOSHhvW0GQR1XS
VMRC-RCZ NEm4TnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCyTWM2OD1zNj6yOVkzKM7:TR?= NXL5OW9bW0GQR1XS
BxPC-3 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rmXmlEPTB;MU[uNlg2PiEQvF2= NU\B[XRpW0GQR1XS
NCI-H2228 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTF4LkWxOVgh|ryP Mm[5V2FPT0WU
NCI-H23 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjaTWM2OD1zNj62NFc5KM7:TR?= NYG2NW54W0GQR1XS
NKM-1 M4ftVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfMTWM2OD1zNz6wNVg6KM7:TR?= M2PBXHNCVkeHUh?=
KYSE-70 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXseIlKSzVyPUG3MlI5QSEQvF2= NEXDfIxUSU6JRWK=
BB49-HNC M2f5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCxTWM2OD1zNz61Olg3KM7:TR?= MXnTRW5ITVJ?
SCC-15 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XhOGlEPTB;MUeuPFQ4OyEQvF2= M4XuNnNCVkeHUh?=
D-247MG M{PqcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LUNGlEPTB;MUeuPVI1PyEQvF2= MV;TRW5ITVJ?
BB30-HNC M3;VNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrieWI1UUN3ME2xPE4xOzF6IN88US=> MUXTRW5ITVJ?
CAL-85-1 M2fCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPxTWM2OD1zOD6xPFA6KM7:TR?= MWLTRW5ITVJ?
HT-3 NGTDdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHmcoNKSzVyPUG4MlM6PzdizszN M1HF[3NCVkeHUh?=
KYSE-410 MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPEcnNKSzVyPUG4MlQ2PzdizszN NXjDZoJJW0GQR1XS
SW982 NH3rW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF6LkW2OFkh|ryP MUjTRW5ITVJ?
SW962 MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF6LkW3NFIh|ryP M2r6SHNCVkeHUh?=
Ramos-2G6-4C10 NV72XYFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF6LkW5Nlch|ryP M4rufnNCVkeHUh?=
OC-314 M2r1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnmyTWM2OD1zOD63N|g1KM7:TR?= MofyV2FPT0WU
LS-123 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorsTWM2OD1zOD63PVAyKM7:TR?= MXXTRW5ITVJ?
D-502MG MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTBb2hJUUN3ME2xPE45OTN7IN88US=> M1q3VnNCVkeHUh?=
RO82-W-1 NHvWZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF6LkiyPFgh|ryP M1PFTXNCVkeHUh?=
HuO9 NID0bmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnW[IxxUUN3ME2xPU4yOzd7IN88US=> M{\aPHNCVkeHUh?=
ETK-1 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF7LkG4Nlch|ryP MXPTRW5ITVJ?
SNU-387 MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF7LkG4PFkh|ryP MXrTRW5ITVJ?
SW1573 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDSS4ZVUUN3ME2xPU4yQTZ7IN88US=> M1XDbnNCVkeHUh?=
NTERA-S-cl-D1 M{HNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDSNJpFUUN3ME2xPU4zODB5IN88US=> NUO5WJFzW0GQR1XS
SF126 M2nkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDyTVZ{UUN3ME2xPU4{PTB{IN88US=> NVnVdmtQW0GQR1XS
Calu-3 NU[zN4VxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXoTWM2OD1zOT60NlM4KM7:TR?= MlPOV2FPT0WU
NCI-H1048 NHfJRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJyLkOyOlYh|ryP NX;qOlNvW0GQR1XS
NCI-H226 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK2RYIzUUN3ME2yNE41Ozl7IN88US=> NY\TW|llW0GQR1XS
FTC-133 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrLWWF2UUN3ME2yNE41PzB|IN88US=> MVLTRW5ITVJ?
SF539 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\6TWRqUUN3ME2yNE42OTd{IN88US=> NV7oS3QyW0GQR1XS
TE-6 NUjadotqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DjNWlEPTB;MkCuPFA3PyEQvF2= NXO3fJN7W0GQR1XS
UMC-11 NYXQdWRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\VVWZKSzVyPUKwMlkyPjRizszN MoHrV2FPT0WU
Becker NIm5d4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;kSWRKSzVyPUKxMlEyOThizszN NHPxUm5USU6JRWK=
KP-4 NVPkboZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;nZmlEPTB;MkGuNVE6PiEQvF2= MWPTRW5ITVJ?
ChaGo-K-1 NFz4S4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJzLkO2Nlch|ryP Mmi2V2FPT0WU
CFPAC-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWftU|FUUUN3ME2yNU4{QDV6IN88US=> NH3SSFVUSU6JRWK=
A498 M3rSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DJR2lEPTB;MkGuOVMyOiEQvF2= MnfWV2FPT0WU
NCI-H1755 M37CN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\kXplKSzVyPUKxMlY4PDFizszN MnPWV2FPT0WU
TI-73 NIPFT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJ{LkOyPEDPxE1? M1fn[3NCVkeHUh?=
NCI-H441 M4O0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ{LkW2PFkh|ryP MnHCV2FPT0WU
CaR-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q4SmlEPTB;MkOuNFIyOyEQvF2= M4nXdHNCVkeHUh?=
HCC1806 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[5XWlEPTB;MkOuNFU5OyEQvF2= M2G1N3NCVkeHUh?=
SNU-449 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnLeYFKSzVyPUKzMlMzQSEQvF2= NGHWZnRUSU6JRWK=
EKVX NXHLVpR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfNV|ZKSzVyPUKzMlM6ODlizszN NH6xOZJUSU6JRWK=
DMS-114 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6yXGl{UUN3ME2yN{42PzZ3IN88US=> MVPTRW5ITVJ?
A704 NFP2eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJ|Lk[xNFMh|ryP MmG0V2FPT0WU
LC-2-ad NH3XUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDWTVNtUUN3ME2yN{43OTR5IN88US=> M17Zc3NCVkeHUh?=
VM-CUB-1 M3XIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfsbnZMUUN3ME2yN{44OzRzIN88US=> NV32TFZSW0GQR1XS
PC-3 NF25WFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG0R4pKSzVyPUK0MlA2OjZizszN NUL3boZQW0GQR1XS
HEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljLTWM2OD1{ND6wPFY2KM7:TR?= M4f5fXNCVkeHUh?=
ABC-1 M2DD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn1UWlsUUN3ME2yOE4zPzJ7IN88US=> M4XKb3NCVkeHUh?=
COLO-680N MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTKTWM2OD1{ND60O|Y1KM7:TR?= M4Lub3NCVkeHUh?=
MZ1-PC M4fmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJ2Lk[4O{DPxE1? M1;re3NCVkeHUh?=
NCI-H69 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJ2LkezOVQh|ryP NX7yS|Z{W0GQR1XS
TE-1 M2XZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrtOW9RUUN3ME2yOU4xPDl7IN88US=> NEjYWVNUSU6JRWK=
EW-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ3LkGxN{DPxE1? MmLCV2FPT0WU
PANC-08-13 MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HkfGlEPTB;MkWuPFExOyEQvF2= NVruTYY4W0GQR1XS
NMC-G1 M3XueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUeyVFloUUN3ME2yOk4xODh6IN88US=> Mn7lV2FPT0WU
BT-20 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTVOHRKSzVyPUK2MlQ2PDNizszN MYXTRW5ITVJ?
TGBC24TKB NIPzRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzzS49KSzVyPUK2Mlc{OzFizszN NVzEOHQzW0GQR1XS
TE-11 NG\VWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[yTWM2OD1{Nj65PFk2KM7:TR?= NXO5cFI1W0GQR1XS
ESS-1 NIn3TpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXQPWp7UUN3ME2yO{4{OjF4IN88US=> Mnq2V2FPT0WU
JVM-3 M4LQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j3cmlEPTB;MkeuOlQ4PSEQvF2= MnqxV2FPT0WU
C3A NHz5boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmriTWM2OD1{Nz64OFk3KM7:TR?= MWPTRW5ITVJ?
MDA-MB-157 NILNWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj3dGJKSzVyPUK3Mlg4PTNizszN M2fwPHNCVkeHUh?=
KLE M1HBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrpS|hKSzVyPUK4MlExPThizszN MkjvV2FPT0WU
ES1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHDU2pKSzVyPUK4MlE5OzhizszN M{XPZXNCVkeHUh?=
CAL-120 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i3fmlEPTB;MkiuN|k6QSEQvF2= NH\OelRUSU6JRWK=
NCI-N87 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnWwTWM2OD1{OD61NVA2KM7:TR?= Mn[1V2FPT0WU
RPMI-8226 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPGTWM2OD1{OT6xPFQ{KM7:TR?= MVfTRW5ITVJ?
COR-L88 NWLLeFJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv0bFVrUUN3ME2yPU4zPDF7IN88US=> M1rhdHNCVkeHUh?=
UACC-893 NX\0flVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHDTWM2OD1{OT6zNVM4KM7:TR?= NHXTcHhUSU6JRWK=
C8166 M3XvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfwNWlWUUN3ME2yPU46QTl4IN88US=> NEfYWnJUSU6JRWK=
J82 M3XVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P5TmlEPTB;M{CuPFE1PyEQvF2= NXq0NHBmW0GQR1XS
PFSK-1 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn4dlF2UUN3ME2zNU4xPjV7IN88US=> MUHTRW5ITVJ?
COLO-684 NXzTc4V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXZUIhKSzVyPUOxMlQ{PzRizszN NV3GT5dGW0GQR1XS
CAL-72 NG\YXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTYeWtKSzVyPUOxMlU4OjlizszN M373d3NCVkeHUh?=
SNB75 MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTNzLki5O{DPxE1? MnvzV2FPT0WU
MDA-MB-415 M4T4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLaXZVMUUN3ME2zNU46PzZ{IN88US=> MXTTRW5ITVJ?
SiHa MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnY[|M2UUN3ME2zNk41PzFzIN88US=> NUDYRZJbW0GQR1XS
NCI-H1648 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILuUZNKSzVyPUOyMlk{PDVizszN Mn\NV2FPT0WU
EFO-21 M2\5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:2ZZoyUUN3ME2zN{4xODVizszN M4HPV3NCVkeHUh?=
HCC38 NHz6dGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\memlEPTB;M{OuN|g1OSEQvF2= NHz4T3NUSU6JRWK=
IA-LM MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDtR45KSzVyPUOzMlc5QDlizszN MYfTRW5ITVJ?
CTV-1 NWfJclZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTN|Lkm3PFYh|ryP MlrjV2FPT0WU
NCI-H446 NFLKOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu2VVFKSzVyPUO0MlI3QDlizszN MmfmV2FPT0WU
IST-SL1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn4bYRvUUN3ME2zOE44PDB6IN88US=> NVi3UZM4W0GQR1XS
EW-22 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jXO2lEPTB;M{SuO|c2QSEQvF2= NEfDVY5USU6JRWK=
JEG-3 MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;xPWlEPTB;M{[uNVc3PiEQvF2= NVXTdWt7W0GQR1XS
LU-65 NXLRbGYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7jWI1KSzVyPUO2MlI6QDVizszN NYjadFd1W0GQR1XS
NCI-H596 NELjVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17PPWlEPTB;M{[uPVU6OSEQvF2= NIfTeYpUSU6JRWK=
KNS-81-FD NWLYXJc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3kTWM2OD1|Nz6xOFUh|ryP NEHVdphUSU6JRWK=
NCI-H1793 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7J[nNWUUN3ME2zO{44ODh4IN88US=> MVfTRW5ITVJ?
NCI-H460 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTN6LkC4O|Mh|ryP M2TQXXNCVkeHUh?=
MPP-89 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzwd5B4UUN3ME2zPU42QDh4IN88US=> MlrXV2FPT0WU
D-542MG NHzqS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHNcnNpUUN3ME2zPU45PDN4IN88US=> MUXTRW5ITVJ?
JAR M1ruUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[0XXd4UUN3ME20NE41PzB3IN88US=> Mne3V2FPT0WU
NCI-H209 M3H1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PaZ2lEPTB;NECuOlc4KM7:TR?= MVjTRW5ITVJ?
G-402 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf0OJgyUUN3ME20NU4{QTl|IN88US=> NUn6SIN2W0GQR1XS
IST-MES1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUSzfnRNUUN3ME20Nk4yQTN3IN88US=> MlH0V2FPT0WU
Daoy MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TVdmlEPTB;NEKuOVQ4OSEQvF2= MmLrV2FPT0WU
EW-11 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTFTWM2OD12Mz6xNlEyKM7:TR?= MVPTRW5ITVJ?
Saos-2 NXHHS|k1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjHe3dKSzVyPUSzMlE2OzdizszN M3ywRnNCVkeHUh?=
no-10 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\We2lEPTB;NEOuNVcxOiEQvF2= NVn2OINIW0GQR1XS
HCC1395 NVnYeJFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTR|LkS2OFQh|ryP NYjhXJNrW0GQR1XS
HCE-4 MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELn[pFKSzVyPUSzMlc3PjRizszN NXTlWYZPW0GQR1XS
EW-1 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf2SmFsUUN3ME20N{45ODR7IN88US=> NWHIOmZUW0GQR1XS
OCUB-M MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTR2LkO2N|gh|ryP M1jaVXNCVkeHUh?=
IGR-1 NFGwWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTR2LkSxNVUh|ryP MlTEV2FPT0WU
NCI-H1838 M1ixfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTR2LkSzOFkh|ryP MVvTRW5ITVJ?
NCI-H2405 NWr2UFE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTR2LkWzOEDPxE1? MYjTRW5ITVJ?
GB-1 NXH5VY9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDETWM2OD12ND63OFY{KM7:TR?= M4nFfHNCVkeHUh?=
MG-63 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf5OW56UUN3ME20Ok4xPjl4IN88US=> MV3TRW5ITVJ?
KP-N-YN M1HPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny3TWM2OD12Nj60Olc6KM7:TR?= NF3qfJZUSU6JRWK=
no-11 NX65d4dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXQTWM2OD12Nz6wNlQ1KM7:TR?= NWrv[FJDW0GQR1XS
SW948 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIizcZhKSzVyPUS3MlM{PzdizszN NHOwXGpUSU6JRWK=
CAMA-1 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV75WoRkUUN3ME20O{4{PDN6IN88US=> NW\kZm1JW0GQR1XS
HCC1187 NFuwOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fDdWlEPTB;NEeuOVEh|ryP MY\TRW5ITVJ?
D-392MG MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK0TWM2OD12Nz62OVE3KM7:TR?= MljVV2FPT0WU
647-V Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7NTWM2OD12OT6zOFE1KM7:TR?= NV72fotHW0GQR1XS

... Click to View More Cell Line Experimental Data
In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]
+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]
+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]
+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol, pH 9
For best results, use promptly after mixing. 		10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2
CAS No. 212631-79-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

  • Cobimetinib (GDC-0973, RG7420) New

    Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Phase 3.

  • BI-847325 New

    BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.

  • GDC-0623 New

    GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.

  • Trametinib (GSK1120212)

    Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2.

    Features:More potent than PD0325901 or AZD6244.

  • PD0325901

    PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

  • Selumetinib (AZD6244)

    Selumetinib (AZD6244) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Phase 3.

    Features:First MEK inhibitor being tested in Phase II clinical trials.

  • U0126-EtOH

    U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059.

    Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.

  • PD98059

    PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

    Features:Does not inhibit c-Raf phosphorylated MEK1.

  • Binimetinib (MEK162, ARRY-162, ARRY-438162)

    Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.

  • Refametinib (RDEA119, Bay 86-9766)

    Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID